Copyright
©The Author(s) 2018.
World J Gastroenterol. May 14, 2018; 24(18): 1925-1941
Published online May 14, 2018. doi: 10.3748/wjg.v24.i18.1925
Published online May 14, 2018. doi: 10.3748/wjg.v24.i18.1925
Table 1 Tyrosine kinase inhibitor election based on genes mutations
| Gene | Mutation | TKI. Dose |
| KIT | Exon 11 | Imatinib-Mesylate 400 mg/d |
| Exon 13 | ||
| Exon 17 | ||
| Exon 9 | Imatinib-Mesylate 800 mg/d | |
| PDGFRA | Exon 18. D842V mutation | Sunitinib 50 mg/d |
| Regorafenib 160 mg/d | ||
| Exon 12 | Imatinib-Mesylate 400 mg/d | |
| Exon 14 | ||
| Exon 18. Non D842V mutations. | ||
| Wild-type | Sunitinib 50 mg/d | |
| Regorafenib 160 mg/d |
Table 2 Risk stratification criteria for primary resectable gastrointestinal stromal tumor porposed by Joensuu
| Risk category | Tumour size (cm) | Mitotic index (per 50 HPF) | Primary tumour site |
| Very low risk | ≤ 2.0 | ≤ 5 | Any |
| Low risk | 2.1-5.0 | ≤ 5 | Any |
| Intermediate risk | ≤ 5.0 | 6-10 | Gastric |
| 5.1-10.0 | ≤ 5 | Gastric | |
| High risk | Any | Any | Tumour rupture |
| > 10.0 | Any | Any | |
| Any | > 10 | Any | |
| > 5.0 | > 5 | Any | |
| ≤ 5.0 | > 5 | Non-gastric | |
| 5.1-10.0 | ≤ 5 | Non-gastric |
Table 3 Items that pathology report should include
| Pathology report items |
| Localization |
| Size |
| Number of foci |
| Tumor infiltration |
| Histologic subtype |
| Depth of tumor infiltration |
| Grade of dedifferentation |
| Mitotic rate |
| Ki67 |
| Grade of necrosis |
| Grade of hemorrhage |
| Margins |
| Staging |
| Mutational study |
- Citation: Sanchez-Hidalgo JM, Duran-Martinez M, Molero-Payan R, Rufian-Peña S, Arjona-Sanchez A, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J. Gastrointestinal stromal tumors: A multidisciplinary challenge. World J Gastroenterol 2018; 24(18): 1925-1941
- URL: https://www.wjgnet.com/1007-9327/full/v24/i18/1925.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i18.1925